Zenas BioPharma releases Phase 3 obexelimab data in IgG4-related disease

press release should clarify. IgG4-RD affects roughly 5.3 per 100,000 ... Cybin Unveils Strategies For CYB003 & CYB004 Psychedelic Drug Development.

Share this story

Surfaced by this Google Alert